Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion. There is no effective systemic treatment of this condition. An increase in the adhesion of erythrocytes to vascular endothelium was observed for patients with CRVO, correlated with overexpression of membrane phosphatidylserine

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
• Collaborators: ADDMEDICA SASA; For Drug Consulting; Institut National de la Transfusion Sanguine; Institut National de la Transfusion Sanguine (INTS); Keyrus; Keyrus Biopharma; Robert Debré Hospital
• Treatments: Hydroxyurea

Criteria

Inclusion Criteria:

• Patients of both sexes of at least 45 years of age.

• with social protection

• Presenting CRVO for less than 1 month duration

• With a decrease of visual acuity and with the best corrected visual acuity lower than 6/10 (73 ETDRS letters)

• Signature of informed consent

Exclusion Criteria:

• predictable lack of compliance to the protocol

• monophtalmic patient or any ocular history or condition that could interfere with the study course or results interpretation.

• active systemic disease

• sickle cell disease

• myeloproliferative disease

• myelosuppression

• kidney or liver insufficiency

• ongoing treatment with hydroxycarbamide or anticoagulant

• Pregnancy, breast-feeding, no efficient contraception (for both sexes)

• wish of paternity (for males of al least 45 years of age)